In conclusion, inhibition of salivation with the antimuscarinic pharmaceutical GPB does not reduce uptake of PSMA-ligands or radioiodine in salivary glands, and therefore cannot be recommended as a means to reduce risk of xerostomia after PSMA ligand or 131I radionuclide therapies. Here, FOLH1 is linked to xerostomia.